He also told us we would never see another Canadian success story like RIM, or an innovation, if we signed the TPP. He spoke in opposition to the TPP innovation chapters, but the question specifically is about ISDS. Has your organization looked at the implications it would have on those Canadians you say you employ? Their health costs would go up, their pharmaceutical costs would go up, and under ISDS provisions we could be sued for trying to implement a pharmacare program. Is that part of what you take into account when you're looking at the TPP?
On May 13th, 2016. See this statement in context.